Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

linezolid injection in sodium chloride Highlights


These highlights do not include all the information needed to use LINEZOLID injection safely and effectively. See full prescribing information for LINEZOLID injection.

LINEZOLID injection, for intravenous use

Initial U.S. Approval: 2000


Warnings and Precautions, Serotonin Syndrome (5.3)1/2022
Warnings and Precautions, Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) (5.10)02/2022


Linezolid is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia (1.1); Community-acquired pneumonia (1.2); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis (1.3); Vancomycin-resistant Enterococcus faecium infections. (1.4)

Limitations of Use: (1.5)

  • Linezolid is not indicated for the treatment of Gram-negative infections.
  • The safety and efficacy of Linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid formulations and other antibacterial drugs, linezolid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.6)


Dosage, Route, and Frequency of Administration
InfectionPediatric Patients
(Birth through 11 Years of Age)
Adults and Adolescents (12 Years and Older)Duration (days)
Nosocomial pneumonia (1.1)10 mg/kg intravenously every 8 hours600 mg intravenously every 12 hours10 to 14
Community-acquired pneumonia, including concurrent bacteremia (1.2)
Complicated skin and skin structure infections (1.3)
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia (1.4)10 mg/kg intravenously every 8 hours600 mg intravenously every 12 hours14 to 28
  • Pediatric Patients-The recommended dose is 10 mg per kg intravenously every 8 hours. Linezolid Injection in a single use VisIV™ Container should be used only in pediatric patients who require the entire 600 mg dose and not any fraction thereof. (2.1)


Injection: 600 mg/300 mL (2 mg/mL) linezolid. (3)


  • Known hypersensitivity to linezolid or any of the other product components. (4.1)
  • Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI. (4.2)


  • Myelosuppression: Monitor complete blood counts weekly. Consider discontinuation in patients who develop or have worsening myelosuppression. (5.1)
  • Peripheral and Optic Neuropathy: Reported primarily in patients treated for longer than 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended. (5.2)
  • Serotonin Syndrome: Monitor patients taking serotonergic agents, including antidepressants and opioids, for signs of serotonin syndrome. Patients taking serotonergic antidepressants should receive linezolid only if no other therapies are available. Discontinue serotonergic antidepressants and monitor patients for signs and symptoms of both serotonin syndrome and antidepressant discontinuation. (5.3)
  • A mortality imbalance was seen in an investigational study in linezolid-treated patients with catheter-related bloodstream infections. (5.4)
  • Clostridioides difficile-Associated Diarrhea: Evaluate if diarrhea occurs. (5.5)
  • Potential interactions producing elevation of blood pressure: monitor blood pressure. (5.6)
  • Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (5.9)
  • Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Monitor serum sodium levels regularly in patients at risk of hyponatremia and/or SIADH. (5.10)


Most common adverse reactions (>5% of adult and pediatric patients treated with linezolid) include: diarrhea, vomiting, headache, nausea, and anemia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985, or FDA at 1-800-FDA-1088 or


  • Monoamine oxidase inhibitors and potential for interaction with adrenergic and serotonergic agents. (4.2, 5.3, 5.6, 7, 12.3)


Revised: 2/2022

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event